Evaluation of the Effectiveness of Implementation of Additional Risk Minimization Measures (aRMM) Materials for Xeljanz® (Tofacitinib) / Rheumatoid Arthritis (RA) indication in Nigeria via a Survey among Prescribers: A Non-Interventional Post Authorization Safety Study (PASS).

27/05/2026
01/06/2026
EU PAS number:
EUPAS1000000900
Study
Planned
Documents
Study protocol
Initial protocol
English (524.31 KB - PDF) View document
Study results
Study report
Other information